TY - JOUR
T1 - Alpha-1 antitrypsin deficiency-associated chronic obstructive pulmonary disease
T2 - A family perspective
AU - Anzueto, Antonio
N1 - Funding Information:
Dr. Antonio Anzueto has served on the speakers’ bureaus of Pfizer Inc., Boehringer Ingelheim GmbH, GlaxoSmithKline plc, and Grifols Therapeutics Inc. (manufacturer of alpha-1 antitrypsin augmentation therapy); and on the advisory boards of GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca plc, Novartis Pharma AG, Bayer Healthcare AG, and Pfizer. Medical writing assistance was provided by Jill See, PhD, of QSci Communications, LLC, and funded by Grifols Inc.
Publisher Copyright:
© 2015 Informa Healthcare USA, Inc.
PY - 2015/7/4
Y1 - 2015/7/4
N2 - Alpha-1 antitrypsin (AAT) deficiency (AATD) is a genetic condition that can lead to the early onset of chronic obstructive pulmonary disease (COPD), a disorder that comprises elements of chronic bronchitis and emphysema. AATD is characterized by reduced levels of the AAT protease inhibitor, leading to unrestricted protease activity in the lung, which promotes destruction of lung tissue. In severe cases, patients with AATD have an increased mortality risk and, potentially, a poor quality of life due to more frequent COPD exacerbations and/or limitations on daily activity. However, the burden of AATD on members of the patient's immediate family who may serve as caregivers has not been described. Because the age range at which most patients are diagnosed with AATD may affect the economic status of an individual and/or of a family, it is likely that a diagnosis of AATD may have negative effects that extend beyond those on the diagnosed person to include immediate family members. Here, we review the literature to investigate the impact of the caregiver role of family members in disease states that affect an age group similar to AATD. Furthermore, we provide a case study showing the effect of AATD on immediate family members.
AB - Alpha-1 antitrypsin (AAT) deficiency (AATD) is a genetic condition that can lead to the early onset of chronic obstructive pulmonary disease (COPD), a disorder that comprises elements of chronic bronchitis and emphysema. AATD is characterized by reduced levels of the AAT protease inhibitor, leading to unrestricted protease activity in the lung, which promotes destruction of lung tissue. In severe cases, patients with AATD have an increased mortality risk and, potentially, a poor quality of life due to more frequent COPD exacerbations and/or limitations on daily activity. However, the burden of AATD on members of the patient's immediate family who may serve as caregivers has not been described. Because the age range at which most patients are diagnosed with AATD may affect the economic status of an individual and/or of a family, it is likely that a diagnosis of AATD may have negative effects that extend beyond those on the diagnosed person to include immediate family members. Here, we review the literature to investigate the impact of the caregiver role of family members in disease states that affect an age group similar to AATD. Furthermore, we provide a case study showing the effect of AATD on immediate family members.
KW - augmentation therapy
KW - caregiver
KW - chronic bronchitis
KW - emphysema
UR - http://www.scopus.com/inward/record.url?scp=84939427182&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939427182&partnerID=8YFLogxK
U2 - 10.3109/15412555.2014.974746
DO - 10.3109/15412555.2014.974746
M3 - Review article
C2 - 25474273
AN - SCOPUS:84939427182
SN - 1541-2555
VL - 12
SP - 462
EP - 467
JO - COPD: Journal of Chronic Obstructive Pulmonary Disease
JF - COPD: Journal of Chronic Obstructive Pulmonary Disease
IS - 4
ER -